🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 92 of 857 · Phase 3 first, then by program name

  1. Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat, BI 690517

    Boehringer Ingelheim

    Type 2 diabetes, hypertension, cardiovascular disease

    phase 3 small molecule active

    1 trial

  2. Jardiance 10 mg film-coated tablets, empagliflozin, Placebo matching empagliflozin, film-coated tablets

    Boehringer Ingelheim

    Chronic kidney disease in paediatric patients

    phase 3 small molecule active

    1 trial

  3. Jaypirca 100 mg film-coated tablets, BGB-16673, BGB-16673

    BEONE MEDICINES AUS PTY LTD

    Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL)

    phase 3 small molecule active

    1 trial

  4. Jianpi Lishi Jiedu Granules

    The First People's Hospital of Lianyungang

    Colorectal Adenoma

    phase 3 small molecule active

    1 trial

  5. Jinarc 30 mg tablets, Tolvaptan, Jinarc 15 mg tablets, Samsca 7.5 mg tablets

    Otsuka Beijing Research Institute

    Autosomal Recessive Polycystic Kidney Disease

    phase 3 small molecule active

    1 trial

  6. Jivi 500 IU powder and solvent for solution for injection, Jivi 1000 IU powder and solvent for solution for injection

    Bayer AG

    Severe hemophilia A (<1% FVIII:C)

    phase 3 small molecule active

    1 trial

  7. Juanbi pill

    Universal Integrated

    Juanbi Pill

    phase 3 small molecule active

    1 trial

  8. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets

    Alfasigma S.p.A.

    Rheumatoid arthritis

    phase 3 small molecule active

    1 trial

  9. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets, Composition apart from the active substance otherwise to identical to IMP

    Alfasigma S.p.A.

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  10. Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets, GLPG0634

    Alfasigma S.p.A.

    Polyarticular-course juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  11. KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    3 trials

  12. KAI-9531

    Kailera Therapeutics

    Obesity With Diabetes

    phase 3 small molecule active

    1 trial

  13. KAI-9531, KAI-9531, Identical to kai-9531 solution for injection without active drug, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  14. KALOMIN™ Tab.

    United Therapeutics Europe Ltd

    Acute Bronchitis

    phase 3 small molecule completed

    1 trial

  15. KARDEGIC 75 mg, poudre pour solution buvable en sachet-dose, CLOPIDOGREL, CLOPIDOGREL

    ISTA Pharma Limited

    chronically occluded coronary artery

    phase 3 small molecule active

    1 trial

  16. KAYFANDA 200 microgram hard capsules, KAYFANDA 400 microgram hard capsules, KAYFANDA 600 microgram hard capsules, KAYFANDA 1 200 microgram hard capsules

    Ipsen

    Alagille Syndrome

    phase 3 small molecule active

    1 trial

  17. KB803

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab active

    1 trial

  18. KETAMINE RENAUDIN 50 mg/ml, solution injectable, SODIUM CHLORIDE

    Pari Pharma GmbH

    Adult patients admitted to the ICU and receiving unplanned invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  19. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Advanced NSCLC

    phase 3 small molecule active

    1 trial

  20. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Ningbo Cancer Hospital

    High risk resected melanoma.

    phase 3 small molecule active

    1 trial

  21. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ADSTILADRIN, GEMCITABINE , DOCETAXEL

    Ferring Pharmaceuticals

    High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours

    phase 3 small molecule active

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion

    Disc Medicine

    Patients with advanced, metastatic NSCLC that have not progressed on a standard of care immunotherapy regimen 6 months after initiation of first line treatment.

    phase 3 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 734506

    Wuhan Createrna Science and Technology Co., Ltd

    Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.

    phase 3 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Boehringer Ingelheim

    non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources